Last reviewed · How we verify
tumor-specific TCR-T cells — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
tumor-specific TCR-T cells (tumor-specific TCR-T cells) — Guangzhou FineImmune Biotechnology Co., LTD..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| tumor-specific TCR-T cells TARGET | tumor-specific TCR-T cells | Guangzhou FineImmune Biotechnology Co., LTD. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- tumor-specific TCR-T cells CI watch — RSS
- tumor-specific TCR-T cells CI watch — Atom
- tumor-specific TCR-T cells CI watch — JSON
- tumor-specific TCR-T cells alone — RSS
Cite this brief
Drug Landscape (2026). tumor-specific TCR-T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/tumor-specific-tcr-t-cells. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab